These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 27537383)

  • 21. Preclinical profile of cabazitaxel.
    Vrignaud P; Semiond D; Benning V; Beys E; Bouchard H; Gupta S
    Drug Des Devel Ther; 2014; 8():1851-67. PubMed ID: 25378905
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preclinical antitumor activity of cabazitaxel, a semisynthetic taxane active in taxane-resistant tumors.
    Vrignaud P; Sémiond D; Lejeune P; Bouchard H; Calvet L; Combeau C; Riou JF; Commerçon A; Lavelle F; Bissery MC
    Clin Cancer Res; 2013 Jun; 19(11):2973-83. PubMed ID: 23589177
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular Mechanism Mediating Cytotoxic Activity of Cabazitaxel in Docetaxel-resistant Human Prostate Cancer Cells.
    Watanabe H; Kawakami A; Sato R; Watanabe K; Matsushita Y; Miyake H
    Anticancer Res; 2021 Aug; 41(8):3753-3758. PubMed ID: 34281834
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Docetaxel/cabazitaxel and fatty acid binding protein 5 inhibitors produce synergistic inhibition of prostate cancer growth.
    Carbonetti G; Converso C; Clement T; Wang C; Trotman LC; Ojima I; Kaczocha M
    Prostate; 2020 Jan; 80(1):88-98. PubMed ID: 31661167
    [TBL] [Abstract][Full Text] [Related]  

  • 25. DNA-PKc inhibition overcomes taxane resistance by promoting taxane-induced DNA damage in prostate cancer cells.
    Chao OS; Goodman OB
    Prostate; 2021 Oct; 81(14):1032-1048. PubMed ID: 34297853
    [TBL] [Abstract][Full Text] [Related]  

  • 26. miR-375 induces docetaxel resistance in prostate cancer by targeting SEC23A and YAP1.
    Wang Y; Lieberman R; Pan J; Zhang Q; Du M; Zhang P; Nevalainen M; Kohli M; Shenoy NK; Meng H; You M; Wang L
    Mol Cancer; 2016 Nov; 15(1):70. PubMed ID: 27832783
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Taxane resistance in prostate cancer is mediated by decreased drug-target engagement.
    Gjyrezi A; Xie F; Voznesensky O; Khanna P; Calagua C; Bai Y; Kung J; Wu J; Corey E; Montgomery B; Mace S; Gianolio DA; Bubley GJ; Balk SP; Giannakakou P; Bhatt RS
    J Clin Invest; 2020 Jun; 130(6):3287-3298. PubMed ID: 32478682
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Wnt non-canonical signaling modulates cabazitaxel sensitivity in prostate cancer cells.
    Sennoune SR; Nelius T; Jarvis C; Pruitt K; Kottapalli KR; Filleur S
    PLoS One; 2020; 15(6):e0234078. PubMed ID: 32484838
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Modulation of the Prostate Cancer Resistance Factor Hsp27 by the Chemotherapeutic Drugs Abiraterone, Cabazitaxel, Docetaxel and Enzalutamide.
    Küster JHS; Erb HHH; Ahrend H; Abazid A; Stope MB
    Anticancer Res; 2024 Jul; 44(7):2815-2821. PubMed ID: 38925843
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interplay of Ritonavir-Boosted Oral Cabazitaxel with the Organic Anion-Transporting Polypeptide (OATP) Uptake Transporters and Carboxylesterase 1 in Mice.
    Loos NHC; Ferreira Martins ML; Rijmers J; de Jong D; Lebre MC; Tibben M; Beijnen JH; Schinkel AH
    Mol Pharm; 2024 Apr; 21(4):1952-1964. PubMed ID: 38423793
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular complexity of taxane-induced cytotoxicity in prostate cancer cells.
    Mang J; Merkle K; Heller M; Schüler J; Tolstov Y; Li J; Hohenfellner M; Duensing S
    Urol Oncol; 2017 Jan; 35(1):32.e9-32.e16. PubMed ID: 27692847
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combination Treatment with Orlistat-Containing Nanoparticles and Taxanes Is Synergistic and Enhances Microtubule Stability in Taxane-Resistant Prostate Cancer Cells.
    Souchek JJ; Davis AL; Hill TK; Holmes MB; Qi B; Singh PK; Kridel SJ; Mohs AM
    Mol Cancer Ther; 2017 Sep; 16(9):1819-1830. PubMed ID: 28615298
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cabazitaxel is more active than first-generation taxanes in ABCB1(+) cell lines due to its reduced affinity for P-glycoprotein.
    Duran GE; Derdau V; Weitz D; Philippe N; Blankenstein J; Atzrodt J; Sémiond D; Gianolio DA; Macé S; Sikic BI
    Cancer Chemother Pharmacol; 2018 Jun; 81(6):1095-1103. PubMed ID: 29675746
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ABCC4 Decreases docetaxel and not cabazitaxel efficacy in prostate cancer cells in vitro.
    Oprea-Lager DE; Bijnsdorp IV; VAN Moorselaar RJ; VAN DEN Eertwegh AJ; Hoekstra OS; Geldof AA
    Anticancer Res; 2013 Feb; 33(2):387-91. PubMed ID: 23393328
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The influence of treatment sequence in the prognostic value of TMPRSS2-ERG as biomarker of taxane resistance in castration-resistant prostate cancer.
    Marín-Aguilera M; Reig Ò; Milà-Guasch M; Font A; Domènech M; Rodríguez-Vida A; Carles J; Suárez C; Del Alba AG; Jiménez N; Victoria I; Sala-González N; Ribal MJ; López S; Etxaniz O; Anguera G; Maroto P; Fernández PL; Prat A; Mellado B
    Int J Cancer; 2019 Oct; 145(7):1970-1981. PubMed ID: 30807643
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Kinesin Facilitates Phenotypic Targeting of Therapeutic Resistance in Advanced Prostate Cancer.
    Archer M; Begemann D; Gonzalez-Kozlova E; Nepali PR; Labanca E; Shepherd P; Dogra N; Navone N; Kyprianou N
    Mol Cancer Res; 2024 Aug; 22(8):730-745. PubMed ID: 38648082
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intra versus Inter Cross-resistance Determines Treatment Sequence between Taxane and AR-Targeting Therapies in Advanced Prostate Cancer.
    Lombard AP; Liu L; Cucchiara V; Liu C; Armstrong CM; Zhao R; Yang JC; Lou W; Evans CP; Gao AC
    Mol Cancer Ther; 2018 Oct; 17(10):2197-2205. PubMed ID: 29891490
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Taxane-based Combination Therapies for Metastatic Prostate Cancer.
    Corn PG; Agarwal N; Araujo JC; Sonpavde G
    Eur Urol Focus; 2019 May; 5(3):369-380. PubMed ID: 29275145
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Exploitation of the Androgen Receptor to Overcome Taxane Resistance in Advanced Prostate Cancer.
    Martin SK; Kyprianou N
    Adv Cancer Res; 2015; 127():123-58. PubMed ID: 26093899
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Contribution of hepatic organic anion-transporting polypeptides to docetaxel uptake and clearance.
    Lee HH; Leake BF; Teft W; Tirona RG; Kim RB; Ho RH
    Mol Cancer Ther; 2015 Apr; 14(4):994-1003. PubMed ID: 25695959
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.